Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medications development for alcohol use disorders

C Wright1

  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA.

Psychopharmacology Bulletin
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Long-term outcome of the anal fistula plug for anal fistula of cryptoglandular origin.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Studies of aging in ames dwarf mice: Effects of caloric restriction.

Journal of the American Aging Association·2013
Same author

Growth hormone and aging.

Journal of the American Aging Association·2013
Same author

Acquisition and utilisation of anthropometric measurements on admission in a paediatric hospital before and after the introduction of a malnutrition screening tool.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2013
Same author

Emergency hospital admissions for the elderly: insights from the Devon Predictive Model.

Journal of public health (Oxford, England)·2013
Same journal

Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients.

Psychopharmacology bulletin·2026
Same journal

Escitalopram-Induced Spasmodic Torticollis in an Early Psychosis Service: A Case Report.

Psychopharmacology bulletin·2026
Same journal

Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship.

Psychopharmacology bulletin·2026
Same journal

Association of CBC-Derived Indices of Inflammation with Response to Glecaprevir/Pibrentasvir for PTSD.

Psychopharmacology bulletin·2026
Same journal

When Care Becomes Dangerous: Patient Assaults Against Physicians.

Psychopharmacology bulletin·2026
Same journal

Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Psychopharmacology bulletin·2026
See all related articles

Grant-funded research and commercial pharmaceutical development for alcohol addiction differ significantly. Strategies for successful clinical trials and new interventions are crucial for effective alcohol use disorder treatment.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Addiction Research

Background:

  • Grant-funded research and commercial pharmaceutical development have distinct objectives and processes.
  • Clinical trials in alcohol addiction present unique challenges.
  • Effective drug development requires specific strategies for controlled trials.

Purpose of the Study:

  • To delineate the differences between grant-funded research and commercial pharmaceutical development in alcohol addiction.
  • To outline strategies for successful clinical trials in alcohol use disorder drug development.
  • To discuss potential new pharmacological interventions and their application across diverse patient presentations.

Main Methods:

  • Comparative analysis of research objectives and processes.

Related Experiment Videos

  • Review of clinical trial design considerations for alcohol addiction.
  • Exploration of strategies to enhance controlled trial success.
  • Discussion of audit considerations in clinical trials.
  • Identification of potential pharmacological interventions.

    • Main Results:

    • Substantial differences exist in the aims and methodologies of academic research versus commercial drug development.
    • Specific strategies are proposed to improve the success rates of controlled trials for alcohol addiction treatments.
    • Potential new pharmacological interventions for alcohol use disorders are identified.
    • The importance of considering medication utility across the spectrum of clinical presentations is highlighted.

    Conclusions:

    • Recognizing and navigating the differences between research types is key for advancing alcohol addiction pharmacotherapy.
    • Optimized clinical trial designs and strategic approaches are essential for successful drug development in this field.
    • Future pharmacological interventions should address the full range of alcohol use disorder presentations.